Making a difference to the people we help treat by creating value and improving healthcare outcomes through connecting innovative manufacturers with Australasian customers.

The 2024-25 Merck Analyte Quarterly Update is Here!

Beyond Biomarkers! 

Expect reliable measurements, a simplified user experience, and knowledgeable scientific partners to help drive your biomarker projects.

Merck’s high-quality and limitation-lifting immunoassay platforms, such as MILLIPLEX® multiplex panels, single-molecule count (SMCR) ultrasensitive (at femtograms/mL sensibility) immunoassays, ELISAs, and RIAs, provide you with all the Assay Capabilities to take your biomarker research further.

This is updated with all our recent launches:

 


The tables below, from Analyte Quarterly 2024-25, highlights the new assays introduced by Merck.

Milliplex Panels

Description

Species

Cat No.

Exosome Characterization Panel

Human

HEXSM-170K

PLEXpedition Screening Panel

Human

HPLX1-115SP

PLEXpedition Screening Premixed 80-Plex Kit

Human

HPLX1-115SP-PX80

PLEXpedition Screening Premixed 115-Plex Kit

Human

HPLX1-115SP-PX


SMC® Kits

Description

Species

Cat No.

IFNλ1 High Sensitivity Immunoassay Kit

Human

03-0213-00

pTau 217 High Sensitivity Immunoassay Kit

Human

03-0210-00

pTau 231 High Sensitivity Immunoassay Kit

Human

03-0211-00


 

2024-25 Merck Analyte Quarterly Update

Download Here >

Download the MILLIPLEX PLEXpedition Screening Panel FL-MK brochure

Download Here >

Learn MILLIPLEX Multiplex assay tips and tricks with this user guide

Download Here >

THESE PRODUCTS ARE NOT AVAILABLE FOR PURCHASE BY THE GENERAL PUBLIC.



Request a Quote

Request Quote

Recent Posts

2027 Abacus dx Emerging Investigators Grant

COMING SOON Grant in Research Funding Empowering the Next Generation of Scientific Leaders Stay tuned for the 2027 Abacus dx Emerging Investigators Grant. More information…

Read full article

Developing Diagnostic Kits for Ovarian Cancer

In Australia, ovarian cancer is the deadliest reproductive cancer. The average five‑year survival rate sits at around 49%, compared with about 92% for breast cancer,…

Read full article

Merck FemtoQuest™

Gain your desired immunoassay sensitivity with the ultrasensitive FemtoQuest™ system Measure down to femtogram/mL levels Improved precision and robust data Perform dual-plex and single analyte…

Read full article